AU2018314280B2 - Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells - Google Patents

Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells Download PDF

Info

Publication number
AU2018314280B2
AU2018314280B2 AU2018314280A AU2018314280A AU2018314280B2 AU 2018314280 B2 AU2018314280 B2 AU 2018314280B2 AU 2018314280 A AU2018314280 A AU 2018314280A AU 2018314280 A AU2018314280 A AU 2018314280A AU 2018314280 B2 AU2018314280 B2 AU 2018314280B2
Authority
AU
Australia
Prior art keywords
eye
cells
compound
retinal
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018314280A
Other languages
English (en)
Other versions
AU2018314280A1 (en
Inventor
Claude Chapman
Jamie Dananberg
Nathaniel David
Agnieszka DEJDA
Jill Hopkins
Remi-Martin LABERGE
Daniel Marquess
Yan Poon
Przemyslaw SAPIEHA
Harry Sweigard
Pam Tsuruda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rsem SC
Unity Biotechnology Inc
Original Assignee
Rsem SC
Unity Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/675,171 external-priority patent/US20180000816A1/en
Application filed by Rsem SC, Unity Biotechnology Inc filed Critical Rsem SC
Publication of AU2018314280A1 publication Critical patent/AU2018314280A1/en
Application granted granted Critical
Publication of AU2018314280B2 publication Critical patent/AU2018314280B2/en
Priority to AU2023251388A priority Critical patent/AU2023251388B2/en
Assigned to UNIVERSITY OF MONTREAL, UNITY BIOTECHNOLOGY, INC. reassignment UNIVERSITY OF MONTREAL Amend patent request/document other than specification (104) Assignors: BUCK INSTITUTE FOR RESEARCH ON AGING, UNITY BIOTECHNOLOGY, INC.
Assigned to UNITY BIOTECHNOLOGY, INC., RSEM, SOCIÉTÉ EN COMMANDITE reassignment UNITY BIOTECHNOLOGY, INC. Request to Amend Deed and Register Assignors: UNITY BIOTECHNOLOGY, INC., UNIVERSITY OF MONTREAL
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018314280A 2017-08-11 2018-08-13 Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells Active AU2018314280B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023251388A AU2023251388B2 (en) 2017-08-11 2023-10-16 Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15/675,171 2017-08-11
US15/675,171 US20180000816A1 (en) 2015-02-06 2017-08-11 Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
US201762579793P 2017-10-31 2017-10-31
US62/579,793 2017-10-31
PCT/US2018/046553 WO2019033119A1 (en) 2017-08-11 2018-08-13 TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023251388A Division AU2023251388B2 (en) 2017-08-11 2023-10-16 Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells

Publications (2)

Publication Number Publication Date
AU2018314280A1 AU2018314280A1 (en) 2020-02-27
AU2018314280B2 true AU2018314280B2 (en) 2023-07-20

Family

ID=63254539

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018314280A Active AU2018314280B2 (en) 2017-08-11 2018-08-13 Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
AU2023251388A Active AU2023251388B2 (en) 2017-08-11 2023-10-16 Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023251388A Active AU2023251388B2 (en) 2017-08-11 2023-10-16 Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells

Country Status (7)

Country Link
EP (2) EP3441069B1 (enExample)
JP (2) JP7278257B2 (enExample)
CN (1) CN111372598A (enExample)
AU (2) AU2018314280B2 (enExample)
CA (1) CA3072673A1 (enExample)
MX (2) MX2020001644A (enExample)
WO (1) WO2019033119A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200354336A9 (en) 2017-08-11 2020-11-12 Unity Biotechnology, Inc. Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
US10588916B2 (en) 2017-10-31 2020-03-17 Unity Biotechnology, Inc. Technology to inhibit vascular changes that lead to vision loss in the eye
JP7089062B2 (ja) 2018-04-30 2022-06-21 ユニティ バイオテクノロジー インコーポレイテッド 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホリジン
US10717722B2 (en) 2018-06-13 2020-07-21 Unity Biotechnology, Inc. Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
AU2019296451B2 (en) 2018-06-29 2021-04-29 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
EP3840785A4 (en) * 2018-08-20 2022-07-13 Wuhan Neurophth Biotechnology Limited Company COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEBERIAN OPTIC ATROPHY
BR112022004515A2 (pt) * 2019-09-13 2022-05-31 Us Health Alvo drogável para tratar a degeneraçâo da retina
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
US20230078120A1 (en) * 2020-05-04 2023-03-16 Ascentage Pharma (Suzhou) Co.,Ltd. Methods for Treating Coronavirus Infections
JP2024501033A (ja) * 2020-12-28 2024-01-10 エムディー ヘルスケア インコーポレイテッド ミクロコッカス・ルテウス由来細胞外小胞を含む眼疾患の予防または治療用組成物
IL305579A (en) 2021-03-01 2023-10-01 Deciduous Therapeutics Inc Compounds for activating invariant natural killer T cells and methods for use in eliminating inflammatory senescent cells
EP4322985A4 (en) * 2021-04-13 2025-02-19 Unity Biotechnology, Inc. METHODS OF TREATMENT OF RETINAL VASCULOPATHIES
KR102625248B1 (ko) * 2021-05-04 2024-01-16 주식회사 퓨전바이오텍 이미다졸린 유도체 화합물을 유효성분으로 포함하는 황반 변성 치료용 약학적 조성물
CN119923390A (zh) * 2022-09-06 2025-05-02 西藏海思科制药有限公司 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用
WO2025009608A1 (ja) * 2023-07-06 2025-01-09 学校法人自治医科大学 生体内物質又は薬物の生体内半閉鎖系における濃度調節剤
CN119925379B (zh) * 2025-03-05 2025-09-05 中南大学湘雅医院 Bcl3抑制剂在制备治疗青光眼的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120189539A1 (en) * 2011-01-25 2012-07-26 The Regents Of University Of Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
WO2015116740A1 (en) * 2014-01-28 2015-08-06 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2016127135A1 (en) * 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditons

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
ATE467791T1 (de) 2001-04-11 2010-05-15 Sumitomo Metal Ind Gewindeverbindungsstück für stahlrohre und verfahren für dessen oberflächenbehandlung
US9804295B2 (en) 2005-05-05 2017-10-31 Novartis Ag Ophthalmic devices for sustained delivery of active compounds
WO2009094466A2 (en) 2008-01-22 2009-07-30 University Of Florida Research Foundation, Inc. Contact lenses for extended release of bioactive agents containing diffusion attenuators
US8353856B2 (en) 2008-11-05 2013-01-15 Abbott Medical Optics Inc. Glaucoma drainage shunts and methods of use
WO2014081953A1 (en) 2012-11-21 2014-05-30 Richard David J Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
KR102318204B1 (ko) 2013-01-16 2021-10-26 더 리젠츠 오브 더 유니버시티 오브 미시간 Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법
US20160122758A1 (en) * 2013-04-21 2016-05-05 Yeda Research And Development Co. Ltd. Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
US20150038140A1 (en) 2013-07-31 2015-02-05 Qualcomm Incorporated Predictive mobility in cellular networks
WO2015017536A1 (en) 2013-07-31 2015-02-05 The Board Of Trustees Of The Leland Stanford Junior University Method and system for evaluating progression of age-related macular degeneration
US20180000816A1 (en) * 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
WO2017008060A1 (en) 2015-07-08 2017-01-12 Unity Biotechnology, Inc. Compositions and methods for treating senescence-associated diseases and disorders
US11111259B2 (en) * 2015-12-18 2021-09-07 Unity Biotechnology, Inc. Acylsulfonamide derivatives for treating senescence-associated diseases and disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120189539A1 (en) * 2011-01-25 2012-07-26 The Regents Of University Of Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
WO2015116740A1 (en) * 2014-01-28 2015-08-06 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2016127135A1 (en) * 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditons

Also Published As

Publication number Publication date
MX2020001644A (es) 2020-07-13
CN111372598A (zh) 2020-07-03
EP4234025A3 (en) 2024-04-24
JP2020530470A (ja) 2020-10-22
CA3072673A1 (en) 2019-02-14
EP3441069A1 (en) 2019-02-13
WO2019033119A1 (en) 2019-02-14
EP4234025A2 (en) 2023-08-30
EP3441069B1 (en) 2023-04-05
AU2023251388B2 (en) 2024-12-12
RU2020109987A (ru) 2021-09-13
JP7278257B2 (ja) 2023-05-19
AU2023251388A1 (en) 2023-11-02
MX2025004366A (es) 2025-05-02
AU2018314280A1 (en) 2020-02-27
JP2023100864A (ja) 2023-07-19

Similar Documents

Publication Publication Date Title
AU2023251388B2 (en) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
US11865123B2 (en) Methods of inhibiting pathological angiogenesis
Scuderi et al. Pigment dispersion syndrome and pigmentary glaucoma: a review and update
De Keyser et al. Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients
Park et al. Clinical effects and safety of 3% diquafosol ophthalmic solution for patients with dry eye after cataract surgery: a randomized controlled trial
Grzybowski et al. The role of steroids and NSAIDs in prevention and treatment of postsurgical cystoid macular edema
US11478465B2 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
TW201440774A (zh) 眼底疾患治療劑
KR20190134588A (ko) 다중 키나아제 억제제 및 안구 섬유증에의 사용
Komizo et al. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma
JP7571037B2 (ja) 眼表面疼痛を治療する方法
US20240342202A1 (en) Methods of Treating Retinal Vasculopathies
Galloway et al. The Ageing Eye
RU2815482C2 (ru) Лечение глазных болезней типа дегенерации желтого пятна, глаукомы и диабетической ретинопатии с помощью лекарственных средств, устраняющих стареющие клетки
HK40032714A (en) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
Narayanaswamy et al. Randomized, controlled trial of a sustained delivery formulation of 5-fluorouracil for the treatment of failing blebs
Fu et al. Cystoid macular edema
ALBÉ et al. Ocular Diseases of Importance to the Refractive Surgeon
HERMAN Endogenous uveitis: Current concepts of treatment
Dikmetas et al. Glaucoma and ocular surface
Garg et al. Ophthalmologic Disease in Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Vallabh et al. Pathology of Glaucoma
Jeganathan et al. Challenges in the management of glaucoma in a patient with severe ocular surface disease: a case report
Patel Development and Evaluation of a Nanomicellar Eye Drop Formulation of Dexamethasone for Posterior Uveitis
EA045318B1 (ru) Соединения для лечения глазных болезней, связанных с избыточной васкуляризацией

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: THE NATURE OF THE AMENDMENT IS: DELETE APPLICANT: BUCK INSTITUTE FOR RESEARCH ON AGING; ADD APPLICANT: UNIVERSITY OF MONTREA; ADD INVENTORS: SAPIEHA, PRZEMYSLAW AND DEJDA, AGNIESZKA

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HOPKINS, JILL; TSURUDA, PAM; CHAPMAN, CLAUDE; SWEIGARD, HARRY; POON, YAN; MARQUESS, DANIEL; DAVID, NATHANIEL; DANANBERG, JAMIE; LABERGE, REMI-MARTIN; SAPIEHA, PRZEMYSLAW AND DEJDA, AGNIESZKA

HB Alteration of name in register

Owner name: UNITY BIOTECHNOLOGY, INC.

Free format text: FORMER NAME(S): UNITY BIOTECHNOLOGY, INC.; BUCK INSTITUTE FOR RESEARCH ON AGING

Owner name: UNIVERSITY OF MONTREAL

Free format text: FORMER NAME(S): UNITY BIOTECHNOLOGY, INC.; BUCK INSTITUTE FOR RESEARCH ON AGING

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: UNITY BIOTECHNOLOGY, INC.

Free format text: FORMER NAME(S): UNITY BIOTECHNOLOGY, INC.; UNIVERSITY OF MONTREAL

Owner name: RSEM, SOCIETE EN COMMANDITE

Free format text: FORMER NAME(S): UNITY BIOTECHNOLOGY, INC.; UNIVERSITY OF MONTREAL